Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurogene (NGNE) Gains from Investment Securities: 2018-2025

Historic Gains from Investment Securities for Neurogene (NGNE) over the last 4 years, with Sep 2025 value amounting to $13,000.

  • Neurogene's Gains from Investment Securities was N/A to $13,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $102,000, marking a year-over-year change of. This contributed to the annual value of $60,000 for FY2024, which is 30.43% up from last year.
  • Neurogene's Gains from Investment Securities amounted to $13,000 in Q3 2025, which was down 7.14% from $14,000 recorded in Q2 2025.
  • Neurogene's Gains from Investment Securities' 5-year high stood at $200,000 during Q2 2023, with a 5-year trough of $5,000 in Q1 2023.
  • Its 3-year average for Gains from Investment Securities is $51,167, with a median of $14,500 in 2025.
  • As far as peak fluctuations go, Neurogene's Gains from Investment Securities spiked by 1,100.00% in 2024, and later plummeted by 75.00% in 2025.
  • Quarterly analysis of 3 years shows Neurogene's Gains from Investment Securities stood at $200,000 in 2023, then spiked by 1,100.00% to $60,000 in 2024, then crashed by 75.00% to $13,000 in 2025.
  • Its Gains from Investment Securities stands at $13,000 for Q3 2025, versus $14,000 for Q2 2025 and $15,000 for Q1 2025.